Publication | Closed Access

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Metastatic Breast CancerOncologyBreast OncologyMedicinePhase Iii TrialLiposomal DoxorubicinBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation Oncology